ArticlePLoS neglected tropical diseases2014
Madurella mycetomatis is highly susceptible to ravuconazole.
Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Eumycetoma causative agents: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma.The Journal of infectious diseases · 2025Trial
- An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.Clinical microbiology reviews · 2024Review
- Article
- Specific and sensitive loop-mediated isothermal amplification (LAMP) method for Madurella strains, eumycetoma filamentous fungi causative agent.PLoS neglected tropical diseases · 2023Article
- The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration.Parasites & vectors · 2023Review
- An update on the development of novel antifungal agents for eumycetoma.Frontiers in pharmacology · 2023Review
- Article
- Mycetoma: Development of Diagnosis and Treatment.Journal of fungi (Basel, Switzerland) · 2022Review
- Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.Mycoses · 2022Article
- Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.PLoS neglected tropical diseases · 2022Article
- In vitro susceptibility testing for black grain eumycetoma causative agents.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Article
- Development and Validation of anAntimicrobial agents and chemotherapy · 2021Article
- Article
- Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.PLoS neglected tropical diseases · 2020Review
- Skin Disease in the Tropics and the Lessons that can be Learned from Leprosy and Other Neglected Diseases.Acta dermato-venereologica · 2020Article
- Pyomelanin Secretion in Madurella mycetomatis Interferes with Spectrophotometric Endpoint Reading Using the Sensititre YeastOne alamarBlue Assay but Not with Visual Endpoint Reading.Antimicrobial agents and chemotherapy · 2019Article
- Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.PLoS neglected tropical diseases · 2018Article
- Fungi that Infect Humans.Microbiology spectrum · 2017Review
- Review of 21 cases of mycetoma from 1991 to 2014 in Rio de Janeiro, Brazil.PLoS neglected tropical diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment of eumycetoma utilizing ketoconazole is unsatisfactory because of high recurrence rates, which often leads to complications and unnecessary amputations, and its comparatively high cost in endemic areas. Hence, an effective and affordable drug is required to improve therapeutic outcome. E1224 is a potent orally available, broad-spectrum triazole currently being developed for the treatment of Chagas disease. E1224 is a prodrug that is rapidly converted to ravuconazole. Plasma levels of E1224 are low and transient, and its therapeutically active moiety, ravuconazole is therapeutically active. In the present study, the in vitro activity of ravuconazole against Madurella mycetomatis, the most common etiologic agent of eumycetoma, was evaluated and compared to that of ketoconazole and itraconazole. Ravuconazole showed excellent activity with MICs ranging between ≤ 0.002 and 0.031 µg/ml, which were significantly lower than the MICs reported for ketoconazole and itraconazole. On the basis of our findings, E1224 with its resultant active moiety, ravuconazole, could be an effective and affordable therapeutic option for the treatment of eumycetoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.